Search

Your search keyword '"Trojani, Alessandra"' showing total 183 results
Start Over Author "Trojani, Alessandra"
183 results on '"Trojani, Alessandra"'

1. Mutational Landscape of Bone Marrow CD19 and CD138 Cells in Waldenström Macroglobulinemia (WM) and IgM Monoclonal Gammopathy of Undetermined Significance (IgM MGUS).

Author

Trojani, Alessandra, Beghini, Alessandro, Bossi, Luca Emanuele, Stefanucci, Marta Rachele, Palumbo, Cassandra, Greco, Antonino, Frustaci, Annamaria, Di Camillo, Barbara, and Cairoli, Roberto

Subjects
*SOMATIC mutation, *FRAMESHIFT mutation, *MISSENSE mutation, *BONE marrow, *CD19 antigen
Abstract

Background: Despite recurrent and activating mutations, including MYD88, CXCR4, ARID1A, KMT2D, and CD79B were identified, the genetic basis for Waldenström's Macroglobulinemia (WM) and the risk of progression of IgM MGUS to WM remain to be fully elucidated. Methods: We investigated the mutation status of WM (n = 8), sWM (n = 7), and IgM MGUS (n = 5) patients, by performing high‐throughput targeted AmpliSeq NGS on 117 target genes. Specifically, we analyzed the CD19+ cells from 15 WM/sWM patients and five IgM MGUS patients. We also analyzed the CD138+ cells from four WM/sWM patients and two IgM MGUS patients. Results: We detected the classic mutation MYD88L265P in 93% of WM/sWM and in 60% of IgM MGUS patients. The CXCR4S338Ter mutation was identified in 26% of WM/sWM patients, whereas it was undetectable in IgM MGUS subjects. Interestingly, we identified new mutated genes, including WNK2 somatic mutations affecting 46% of WM/sWM patients, for which a recurrent allelic variant (V1635Ter) was observed in this cohort. Moreover, sequencing evaluation revealed recurrently frameshift or missense mutations involving NFKB2 (L473Afs) in 60% of IgM MGUS and 20% of WM/sWM, PTPN13 (P1546Tfs) in 20% of IgM MGUS and 7% of WM/sWM, CARD11 (S622del) in 20% of IgM MGUS and 20% of WM/sWM, KMT2C (I823T) in all IgM MGUS and 93% of WM/sWM, and ATM in 20% of IgM MGUS and 47% of WM/sWM patients. Conclusion: In conclusion, we uncovered new insights into the mutational landscape of WM, depicting a more complex involvement of the NF‐kB pathway, and providing evidence of the recurrence of some variants (MYD88, IL17RB, NFKB2, ATM, CARD11, PTPN13, and WNK2) also in IgM MGUS. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

2. Fasting and Diet: Overview in Chronic Lymphocytic Leukemia.

Author

Trojani, Alessandra, Bossi, Luca Emanuele, and Cairoli, Roberto

Subjects
*CHRONIC lymphocytic leukemia, *CANCER cell growth, *DEVIATORIC stress (Engineering), *CANCER patients, WESTERN countries
Abstract

Background: This review aims to provide an overview of the potential impact of fasting and diet on cancer, and in particular, on chronic lymphocytic leukemia (CLL), which is the most frequent form of leukemia in the Western world. Methods: Experimental and clinical studies have provided evidence of the crucial role of fasting in enhancing cancer treatment and improving outcomes for oncological patients, particularly at the early stages of the disease. Results: Emerging evidence highlights that fasting creates a differential stress response under critical conditions by fostering the survival of normal cells while limiting the survival and growth of cancer cells. Pivotal studies on CLL have highlighted the potential of fasting and dietary components to influence the stromal microenvironment and certain metabolic pathways, thereby affecting cancer cell apoptosis and immune response. In addition, explorative and initial clinical studies suggest that fasting and specific diets can mitigate the toxicity of chemotherapy. Conclusions: Clinical trials are needed to evaluate the efficacy and safety of nutritional and fasting approaches in cancer and CLL. Future investigations could provide new insights into the potential role of diet and fasting in the prevention and treatment of cancer, potentially leading to more effective and personalized therapeutic strategies. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

3. Fasting and Diet: Overview in Chronic Lymphocytic Leukemia

Author

Trojani, A, Bossi, L, Cairoli, R, Trojani, Alessandra, Bossi, Luca Emanuele, Cairoli, Roberto, Trojani, A, Bossi, L, Cairoli, R, Trojani, Alessandra, Bossi, Luca Emanuele, and Cairoli, Roberto

Abstract

Background: This review aims to provide an overview of the potential impact of fasting and diet on cancer, and in particular, on chronic lymphocytic leukemia (CLL), which is the most frequent form of leukemia in the Western world. Methods: Experimental and clinical studies have provided evidence of the crucial role of fasting in enhancing cancer treatment and improving outcomes for oncological patients, particularly at the early stages of the disease. Results: Emerging evidence highlights that fasting creates a differential stress response under critical conditions by fostering the survival of normal cells while limiting the survival and growth of cancer cells. Pivotal studies on CLL have highlighted the potential of fasting and dietary components to influence the stromal microenvironment and certain metabolic pathways, thereby affecting cancer cell apoptosis and immune response. In addition, explorative and initial clinical studies suggest that fasting and specific diets can mitigate the toxicity of chemotherapy. Conclusions: Clinical trials are needed to evaluate the efficacy and safety of nutritional and fasting approaches in cancer and CLL. Future investigations could provide new insights into the potential role of diet and fasting in the prevention and treatment of cancer, potentially leading to more effective and personalized therapeutic strategies.

Published
2024

6. Mutational Landscape of Bone Marrow CD19 and CD138 Cells in Waldenström Macroglobulinemia (WM) and IgM Monoclonal Gammopathy of Undetermined Significance (IgM MGUS)

Author

Trojani, A, Beghini, A, Bossi, L, Stefanucci, M, Palumbo, C, Greco, A, Frustaci, A, Di Camillo, B, Montillo, M, Cairoli, R, Trojani, Alessandra, Beghini, Alessandro, Bossi, Luca Emanuele Emanuele, Stefanucci, Marta Rachele, Palumbo, Cassandra, Greco, Antonino, Frustaci, Annamaria, Di Camillo, Barbara, Montillo, Marco, Cairoli, Roberto, Trojani, A, Beghini, A, Bossi, L, Stefanucci, M, Palumbo, C, Greco, A, Frustaci, A, Di Camillo, B, Montillo, M, Cairoli, R, Trojani, Alessandra, Beghini, Alessandro, Bossi, Luca Emanuele Emanuele, Stefanucci, Marta Rachele, Palumbo, Cassandra, Greco, Antonino, Frustaci, Annamaria, Di Camillo, Barbara, Montillo, Marco, and Cairoli, Roberto

Published
2023

7. A Nine-Gene Expression Signature Distinguished a Patient with Chronic Lymphocytic Leukemia Who Underwent Prolonged Periodic Fasting

Author

Bossi, L, Palumbo, C, Trojani, A, Melluso, A, Di Camillo, B, Beghini, A, Sarnataro, L, Cairoli, R, Bossi, Luca Emanuele, Palumbo, Cassandra, Trojani, Alessandra, Melluso, Agostina, Di Camillo, Barbara, Beghini, Alessandro, Sarnataro, Luca Maria, Cairoli, Roberto, Bossi, L, Palumbo, C, Trojani, A, Melluso, A, Di Camillo, B, Beghini, A, Sarnataro, L, Cairoli, R, Bossi, Luca Emanuele, Palumbo, Cassandra, Trojani, Alessandra, Melluso, Agostina, Di Camillo, Barbara, Beghini, Alessandro, Sarnataro, Luca Maria, and Cairoli, Roberto

Abstract

Background and Objectives: This study aimed to investigate the causes of continuous deep fluctuations in the absolute lymphocyte count (ALC) in an untreated patient with Chronic Lymphocytic Leukemia (CLL), who has had a favorable prognosis since the time of diagnosis. Up until now, the patient has voluntarily chosen to adopt a predominantly vegetarian and fruitarian diet, along with prolonged periods of total fasting (ranging from 4 to 39 days) each year. Materials and Methods: For this purpose, we decided to analyze the whole transcriptome profiling of peripheral blood (PB) CD19+ cells from the patient (#1) at different time-points vs. the same cells of five other untreated CLL patients who followed a varied diet. Consequently, the CLL patients were categorized as follows: the 1st group comprised patient #1 at 20 different time-points (16 time-points during nutrition and 4 time-points during fasting), whereas the 2nd group included only one time point for each of the patients (#2, #3, #4, #5, and #6) as they followed a varied diet. We performed microarray experiments using a powerful tool, the Affymetrix Human ClariomTM D Pico Assay, to generate high-fidelity biomarker signatures. Statistical analysis was employed to identify differentially expressed genes and to perform sample clustering. Results: The lymphocytosis trend in patient #1 showed recurring fluctuations since the time of diagnosis. Interestingly, we observed that approximately 4–6 weeks after the conclusion of fasting periods, the absolute lymphocyte count was reduced by about half. The gene expression profiling analysis revealed that nine genes were statistically differently expressed between the 1st group and the 2nd group. Specifically, IGLC3, RPS26, CHPT1, and PCDH9 were under expressed in the 1st group compared to the 2nd group of CLL patients. Conversely, IGHV3-43, IGKV3D-20, PLEKHA1, CYBB, and GABRB2 were over-expressed in the 1st group when compared to the 2nd group of CLL patients. Furthermore

Published
2023

8. Occurrence of L1M Elements in Chromosomal Rearrangements Associated to Chronic Myeloid Leukemia (CML): Insights from Patient-Specific Breakpoints Characterization

Author

L’Abbate, Alberto, primary, Moretti, Vittoria, additional, Pungolino, Ester, additional, Micheloni, Giovanni, additional, Valli, Roberto, additional, Frattini, Annalisa, additional, Barcella, Matteo, additional, Acquati, Francesco, additional, Reinbold, Rolland A, additional, Costantino, Lucy, additional, Ferrara, Fulvio, additional, Trojani, Alessandra, additional, Ventura, Mario, additional, Porta, Giovanni, additional, and Cairoli, Roberto, additional

Published
2023
Full Text
View/download PDF

9. The ERK1/2 Regulator WNK2 Shows Novel Alternative Splicing Aberrations That Support Tumor Growth in MYD88 Mutated Waldenström's Macroglobulinemia

Author

Guerrera, Maria Luisa, primary, Liu, Xia, additional, Morelli, Eugenio, additional, Richardson, Kris, additional, Tsakmaklis, Nickolas, additional, Kofides, Amanda, additional, Munshi, Manit, additional, Liu, Shirong, additional, Yang, Guang, additional, Patterson, Christopher J, additional, Castillo, Jorge J., additional, Sarosiek, Shayna, additional, Flynn, Catherine A., additional, Meid, Kirsten, additional, Gustine, Joshua, additional, Branagan, Andrew R., additional, Trojani, Alessandra, additional, Tedeschi, Alessandra, additional, Cairoli, Roberto, additional, Sewastianik, Tomasz, additional, Carrasco, Ruben D., additional, Anderson, Kenneth C., additional, Munshi, Nikhil C, additional, Treon, Steven P, additional, and Hunter, Zachary R, additional

Published
2022
Full Text
View/download PDF

11. MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction

Author

Xu, Lian, Hunter, Zachary R., Yang, Guang, Zhou, Yangsheng, Cao, Yang, Liu, Xia, Morra, Enrica, Trojani, Alessandra, Greco, Antonino, Arcaini, Luca, Varettoni, Marzia, Brown, Jennifer R., Tai, Yu-Tzu, Anderson, Kenneth C., Munshi, Nikhil C., Patterson, Christopher J., Manning, Robert J., Tripsas, Christina K., Lindeman, Neal I., and Treon, Steven P.

Published
2013
Full Text
View/download PDF

12. Cordycepin (3′dA) Induces Cell Death of AC133 + Leukemia Cells via Re-Expression of WIF1 and Down-Modulation of MYC.

Author

Abazari, Nazanin, Stefanucci, Marta Rachele, Bossi, Luca Emanuele, Trojani, Alessandra, Cairoli, Roberto, and Beghini, Alessandro

Subjects
DRUG efficacy, LEUKEMIA, CELL survival, STEM cells, RESEARCH funding, ADENOSINES, TRANSCRIPTION factors, CELL lines, DATA analysis software, CELL death
Abstract

Simple Summary: Cordycepin, an analog of adenosine, has shown anti-leukemic properties towards leukemic stem cells (LSCs) by perturbing the leukemia−stroma association. However, the full molecular picture has not been fully elucidated. In addition, Wnt/β-catenin signaling is required for LSC development and maintenance in acute myeloid leukemia (AML). Here we show that cordycepin downregulates the Wnt target genes MYC and PROM1 (CD133), critical factors in stem cell maintenance, via re-expression of WIF1 and DKK1. The results provided offer new insights into the molecular circuits involved in the cordycepin-mediated inhibition of Wnt signaling. This mechanism of action of cordycepin has potential applications in treating AML. Wnt/β-catenin signaling is critically required for the development and maintenance of leukemia stem cells (LSCs) in acute myeloid leukemia (AML) by constitutive activation of myeloid regeneration-related pathways. Cell-intrinsic activation of canonical Wnt signaling propagates in the nucleus by β-catenin translocation, where it induces expression of target oncogenes such as JUN, MYC and CCND1. As the Wnt/β−catenin pathway is now well established to be a key oncogenic signaling pathway promoting leukemic myelopoiesis, targeting it would be an effective strategy to impair LSC functionality. Although the effects of the adenosine analogue cordycepin in repressing β-catenins and destabilizing the LSC niche have been highlighted, the cellular and molecular effects on AML–LSC have not been fully clarified. In the present study, we evaluated the potency and efficacy of cordycepin, a selective repressor of Wnt/β-catenin signaling with anti-leukemia properties, on the AC133+ LSC fraction. Cordycepin effectively reduces cell viability of the AC133+ LSCs in the MUTZ−2 cell model and patient-derived cells through the induction of apoptosis. By Wnt-targeted RNA sequencing panel, we highlighted the re-expression of WIF1 and DKK1 among others, and the consequent downregulation of MYC and PROM1 (CD133) following MUTZ−2 cell exposure to increasing doses of cordycepin. Our results provide new insights into the molecular circuits involved in pharmacological inhibition mediated by cordycepin reinforcing the potential of targeting the Wnt/β-catenin and co-regulatory complexes in AML. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

13. Occurrence of L1M Elements in Chromosomal Rearrangements Associated to Chronic Myeloid Leukemia (CML): Insights from Patient-Specific Breakpoints Characterization.

Author

L'Abbate, Alberto, Moretti, Vittoria, Pungolino, Ester, Micheloni, Giovanni, Valli, Roberto, Frattini, Annalisa, Barcella, Matteo, Acquati, Francesco, Reinbold, Rolland A, Costantino, Lucy, Ferrara, Fulvio, Trojani, Alessandra, Ventura, Mario, Porta, Giovanni, and Cairoli, Roberto

Subjects
CHRONIC myeloid leukemia, CHROMOSOMAL rearrangement, PHILADELPHIA chromosome, PROTEIN-tyrosine kinases, CHROMOSOMAL translocation, BLOOD pressure
Abstract

Chronic myeloid leukemia (CML) is a rare myeloproliferative disorder caused by the reciprocal translocation t(9;22)(q34;q11) in hematopoietic stem cells (HSCs). This chromosomal translocation results in the formation of an extra-short chromosome 22, called a Philadelphia chromosome (Ph), containing the BCR-ABL1 fusion gene responsible for the expression of a constitutively active tyrosine kinase that causes uncontrolled growth and replication of leukemic cells. Mechanisms behind the formation of this chromosomal rearrangement are not well known, even if, as observed in tumors, repetitive DNA may be involved as core elements in chromosomal rearrangements. We have participated in the explorative investigations of the PhilosoPhi34 study to evaluate residual Ph+ cells in patients with negative FISH analysis on CD34+/lin- cells with gDNA qPCR. Using targeted next-generation deep sequencing strategies, we analyzed the genomic region around the t(9;22) translocations of 82 CML patients and one CML cell line and assessed the relevance of interspersed repeat elements at breakpoints (BP). We found a statistically higher presence of LINE elements, in particular belonging to the subfamily L1M, in BP cluster regions of both chromosome 22 and 9 compared to the whole human genome. These data suggest that L1M elements could be potential drivers of t(9;22) translocation leading to the generation of the BCR-ABL1 chimeric gene and the expression of the active BCR-ABL1-controlled tyrosine kinase chimeric protein responsible for CML. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

14. FZD6 triggers Wnt–signalling driven by WNT10BIVS1 expression and highlights new targets in T‐cell acute lymphoblastic leukemia

Author

Cassaro, Adriana, Grillo, Giovanni, Notaro, Marco, Gliozzo, Jessica, Esposito, Ilaria, Reda, Gianluigi, Trojani, Alessandra, Valentini, Giorgio, Di Camillo, Barbara, Cairoli, Roberto, Beghini, Alessandro, Adriana, C, Giovanni, G, Marco, N, Jessica, G, Ilaria, E, Gianluigi, R, Alessandra, T, Giorgio, V, Barbara Di, C, Cairoli, R, and Alessandro, B

Subjects
Male, Gene Expression Regulation, Leukemic, Pyridines, Membrane Proteins, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Wnt signaling, Frizzled Receptors, Wnt Proteins, WNT10B, porcupine inhibitor, Original Research Articles, Proto-Oncogene Proteins, Pyrazines, Humans, Female, Original Research Article, T-ALL, FZD6, LGK974, Wnt Signaling Pathway, T‐ALL, Acyltransferases, HeLa Cells
Abstract

Wnt/Fzd signaling has been implicated in hematopoietic stem cell maintenance and in acute leukemia establishment. In our previous work, we described a recurrent rearrangement involving the WNT10B locus (WNT10BR), characterized by the expression of WNT10BIVS1 transcript variant, in acute myeloid leukemia. To determine the occurrence of WNT10BR in T‐cell acute lymphoblastic leukemia (T‐ALL), we retrospectively analyzed an Italian cohort of patients (n = 20) and detected a high incidence (13/20) of WNT10BIVS1 expression. To address genes involved in WNT10B molecular response, we have designed a Wnt‐targeted RNA sequencing panel. Identifying Wnt agonists and antagonists, it results that the expression of FZD6, LRP5, and PROM1 genes stands out in WNT10BIVS1 positive patients compared to negative ones. Using MOLT4 and MUTZ‐2 as leukemic cell models, which are characterized by the expression of WNT10BIVS1, we have observed that WNT10B drives major Wnt activation to the FZD6 receptor complex through receipt of ligand. Additionally, short hairpin RNAs (shRNAs)‐mediated gene silencing and small molecule‐mediated inhibition of WNTs secretion have been observed to interfere with the WNT10B/FZD6 interaction. We have therefore identified that WNT10BIVS1 knockdown, or pharmacological interference by the LGK974 porcupine (PORCN) inhibitor, reduces WNT10B/FZD6 protein complex formation and significantly impairs intracellular effectors and leukemic expansion. These results describe the molecular circuit induced by WNT10B and suggest WNT10B/FZD6 as a new target in the T‐ALL treatment strategy.

Published
2021

16. A Nutritional Approach for the Management of Chemotherapy-Induced Diarrhea in Patients with Colorectal Cancer

Author

Artale, Salvatore, primary, Grillo, Nunziata, additional, Lepori, Stefano, additional, Butti, Chiara, additional, Bovio, Antonella, additional, Barzaghi, Sabrina, additional, Colombo, Andrea, additional, Castiglioni, Elena, additional, Barbarini, Lucia, additional, Zanlorenzi, Laura, additional, Antonelli, Paola, additional, Caccialanza, Riccardo, additional, Pedrazzoli, Paolo, additional, Moroni, Mauro, additional, Basciani, Sabrina, additional, Azzarello, Rebecca, additional, Serra, Francesco, additional, and Trojani, Alessandra, additional

Published
2022
Full Text
View/download PDF

17. Clonal architecture of CXCR4 WHIM-like mutations in Waldenström Macroglobulinaemia

Author

Xu, Lian, Hunter, Zachary R., Tsakmaklis, Nicholas, Cao, Yang, Yang, Guang, Chen, Jie, Liu, Xia, Kanan, Sandra, Castillo, Jorge J., Tai, Yu-Tzu, Zehnder, James L., Brown, Jennifer R., Carrasco, Ruben D., Advani, Ranjana, Sabile, Jean M., Argyropoulos, Kimon, Lia Palomba, M., Morra, Enrica, Trojani, Alessandra, Greco, Antonino, Tedeschi, Alessandra, Varettoni, Marzia, Arcaini, Luca, Munshi, Nikhil M., Anderson, Kenneth C., and Treon, Steven P.

Published
2016
Full Text
View/download PDF

18. Common Gene Expression Signature of B-Cells of Waldenström Macroglobulinemia (WM) and IgM Monoclonal Gammopathies of Undetermined Significance (IgM MGUS) Compared to Healthy Subjects

Author

Trojani, Alessandra, primary, Di Camillo, Barbara, additional, Bossi, Luca Emanuele, additional, Greco, Antonino, additional, Leuzzi, Livia, additional, Tedeschi, Alessandra, additional, Frustaci, Anna Maria, additional, Deodato, Marina, additional, Zamprogna, Giulia, additional, Melluso, Agostina, additional, Panzeri, Alessia, additional, Montillo, Marco, additional, Beghini, Alessandro, additional, and Cairoli, Roberto, additional

Published
2021
Full Text
View/download PDF

19. Identification of a Candidate Gene Set Signature for the Risk of Progression in IgM MGUS to Smoldering/Symptomatic Waldenström Macroglobulinemia (WM) by a Comparative Transcriptome Analysis of B Cells and Plasma Cells

Author

Trojani, Alessandra, Camillo, Barbara Di, Bossi, Luca Emanuele, Leuzzi, Livia, Greco, Antonino, Tedeschi, Alessandra, Frustaci, Anna Maria, Deodato, Marina, Zamprogna, Giulia, Beghini, Alessandro, Cairoli, Roberto, Alessandra, T, Barbara Di, C, Luca Emanuele, B, Livia, L, Antonino, G, Anna Maria, F, Marina, D, Giulia, Z, Alessandro, B, and Cairoli, R

Subjects
IgM monoclonal gammopathies of undetermined significance, KEGG signaling pathways, Waldenström Macroglobulinemia, DEGs (differentially expressed genes), Gene expression profiling, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, lcsh:RC254-282, Article, KEGG signaling pathway, MED/15 - MALATTIE DEL SANGUE, immune system diseases, hemic and lymphatic diseases, gene expression profiling
Abstract

Simple Summary IgM monoclonal gammopathy of undetermined significance (IgM MGUS) is an early precursor stage of the rare lymphoma Waldenström Macroglobulinemia (WM). Although comparative gene expression studies on WM, IgM MGUS, and normal B-cells (CTRLs) identified several differentially expressed genes, reliable predictors of progression from IgM MGUS to WM have not yet been identified. We performed a microarray study on CD19+ and CD138+ cells of WM vs. IgM MGUS vs. CTRLs to determine gene signatures for both cell populations. We demonstrated that hematopoietic antigens, cell-adhesion molecules, Wnt-signaling, BCR-signaling, calcium signaling, coagulation cascade, and pathways responsible for cell cycle and proliferation were significantly enriched for genes expressed in B-cells of WM vs. IgM MGUS vs. CTRLs. Interestingly, we showed nine genes which displayed the same expression levels in WM and IgM MGUS compared to CTRLs, suggesting their possible role in the risk of transformation of IgM MGUS to WM. Abstract Waldenström Macroglobulinemia (WM) is a B-cell lymphoma characterized by the precursor condition IgM monoclonal gammopathies of undetermined significance (IgM MGUS). We performed a gene expression profiling study to compare the transcriptome signatures of bone marrow (BM) B-cells and plasma cells of 36 WM patients, 13 IgM MGUS cases, and 7 healthy subjects used as controls (CTRLs) by Affymetrix microarray. We determined 2038 differentially expressed genes (DEGs) in CD19+ cells and 29 DEGs genes in CD138+ cells, respectively. The DEGs identified in B-cells were associated with KEGG pathways, mainly involved in hematopoietic cell lineage antigens, cell adhesion/focal adhesion/transmembrane proteins, adherens junctions, Wnt-signaling pathway, BCR-signaling pathway, calcium signaling pathway, complement/coagulation cascade, platelet activation, cytokine-cytokine receptor interactions, and signaling pathways responsible for cell cycle, apoptosis, proliferation and survival. In conclusion, we showed the deregulation of groups of genes belonging to KEGG pathways in the comparison among WM vs. IgM MGUS vs. CTRLs in B-cells. Interestingly, a small set of genes in B-cells displayed a common transcriptome expression profile between WM and IgM MGUS compared to CTRLs, suggesting its possible role in the risk of transformation of IgM MGUS to WM.

Published
2021

20. Nilotinib‐induced bone marrow CD34+/lin‐Ph+ cells early clearance in newly diagnosed CP‐Chronic Myeloid Leukemia: Final report of the PhilosoPhi34 study

Author

Pungolino, Ester, primary, D'adda, Mariella, additional, De Canal, Gabriella, additional, Trojani, Alessandra, additional, Perego, Alessandra, additional, Elena, Chiara, additional, Lunghi, Francesca, additional, Turrini, Mauro, additional, Borin, Lorenza, additional, Iurlo, Alessandra, additional, Latargia, Maria Luisa, additional, Carraro, Maria Cristina, additional, Spina, Francesco, additional, Artale, Salvatore, additional, Anghilieri, Michela, additional, Molteni, Alfredo, additional, Caramella, Marianna, additional, Baruzzo, Giacomo, additional, Nichelatti, Michele, additional, Di Camillo, Barbara, additional, and Cairoli, Roberto, additional

Published
2021
Full Text
View/download PDF

23. FZD6 triggers Wnt–signalling driven by WNT10B IVS1 expression and highlights new targets in T‐cell acute lymphoblastic leukemia

Author

Cassaro, Adriana, primary, Grillo, Giovanni, additional, Notaro, Marco, additional, Gliozzo, Jessica, additional, Esposito, Ilaria, additional, Reda, Gianluigi, additional, Trojani, Alessandra, additional, Valentini, Giorgio, additional, Di Camillo, Barbara, additional, Cairoli, Roberto, additional, and Beghini, Alessandro, additional

Published
2021
Full Text
View/download PDF

24. In vivo gene therapy of metachromatic leukodystrophy by lentiviral vectors: correction of neuropathology and protection against learning impairments in affected mice

Author

Consiglio, Antonella, Quattrini, Angelo, Martino, Sabata, Bensadoun, Jean Charles, Dolcetta, Diego, Trojani, Alessandra, Benaglia, Giuliana, Marchesini, Sergio, Cestari, Vincenzo, Oliverio, Alberto, Bordignon, Claudio, and Naldini, Luigi

Abstract

Author(s): Antonella Consiglio [1]; Angelo Quattrini [1]; Sabata Martino [1]; Jean Charles Bensadoun [2]; Diego Dolcetta [1]; Alessandra Trojani [1]; Giuliana Benaglia [3]; Sergio Marchesini [3]; Vincenzo Cestari [4]; Alberto [...]

Published
2001
Full Text
View/download PDF

25. Cell Surface Proteins of B Cells and Plasmacells Are Differently Expressed in Waldenström's Macroglobulinemia (WM) Patients Vs. Subjects with Monoclonal Gammopathy of Uncertain Significance (IgMMGUS) Vs. Healthy Donors

Author

Trojani, Alessandra, primary, Di Camillo, Barbara, additional, Bossi, Luca Emanuele, additional, Tedeschi, Alessandra, additional, Frustaci, Annamaria, additional, Beghini, Alessandro, additional, Montillo, Marco, additional, and Cairoli, Roberto, additional

Published
2020
Full Text
View/download PDF

26. Role of Diet in the Management of Carcinoid Syndrome: Clinical Recommendations for Nutrition in Patients with Neuroendocrine Tumors.

Author

Artale, Salvatore, Barzaghi, Sabrina, Grillo, Nunziata, Maggi, Claudia, Lepori, Stefano, Butti, Chiara, Bovio, Antonella, Barbarini, Lucia, Colombo, Andrea, Zanlorenzi, Laura, Castiglioni, Elena, and Trojani, Alessandra

Subjects
TRYPTOPHAN metabolism, DIARRHEA, APPETITE, MEDITERRANEAN diet, GASTROINTESTINAL motility, FOOD Pyramid, INGESTION, LACTOSE intolerance, MALIGNANT carcinoid syndrome, CANCER patients, AMINES, CELIAC disease, NEUROENDOCRINE tumors, MALNUTRITION, HEALTH care teams, GASTROINTESTINAL hormones, PEPTIDES, DISEASE risk factors
Abstract

Nutrition and metabolism are altered in patients with gastroenteropancreatic neuroendocrine tumors, which is related to excessive production of gastrointestinal hormones, peptides, and amines that can cause maldigestion, diarrhea, steatorrhea, and altered gastrointestinal motility. Patients with carcinoid syndrome are at risk of malnutrition due to tryptophan depletion, reduced intake of food, and loss of appetite because of diarrhea and/or flushing. To date, there is limited information on the nutritional issues faced by patients with neuroendocrine tumors, and on what specific recommendations should be made to patients concerning nutrition at various stages of the disease process. Dietary planning should therefore be an integral part of multidisciplinary management for patients with neuroendocrine tumors. Herein, we review current guidance for nutrition in patients with neuroendocrine tumors, focusing on intake of amines and foods to avoid, as well as concurrent medications. We also propose a new and practical food pyramid based on the principles of Mediterranean diet 4.0 that can be easily adapted according to the unmet needs of patients with neuroendocrine tumors at all stages of disease. The overarching goal of the present review is to create greater awareness of nutritional care and considerations that should be given to patients with neuroendocrine tumors. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

27. Transmembrane Receptors, Cytoskeleton and Cell Cycle Genes Were Progressively Deregulated in the Bone Marrow CD19+ and CD138+ Cells of Patientswwith Waldenstrom's Macroglolubinemia (WM) Vs. Subjects with IgM Monoclonal Gammopathy of Undetermined Significance Igmmgus Vs. Healthy Subjects

Author

Trojani, Alessandra, primary, Tedeschi, Alessandra, additional, Frustaci, Annamaria Maria, additional, Deodato, Marina, additional, Bossi, Luca Emanuele, additional, Di Camillo, Barbara, additional, Montillo, Marco, additional, Morra, Enrica, additional, and Cairoli, Roberto, additional

Published
2019
Full Text
View/download PDF

28. Progressive Down Regulation of JAK-STAT, Cell Cycle, and ABC Transporter Genes in CD34+/Lin- Cells of Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients at Diagnosis Vs. 12 Months of Nilotinib Treatment Vs. Healthy Subjects

Author

Trojani, Alessandra, primary, Pungolino, Ester, additional, Rossi, Giuseppe, additional, D'adda, Mariella, additional, Bossi, Luca Emanuele, additional, Baruzzo, Giacomo, additional, Di Camillo, Barbara, additional, Perego, Alessandra, additional, Turrini, Mauro, additional, Elena, Chiara, additional, Borin, Lorenza Maria, additional, Iurlo, Alessandra, additional, Malato, Simona, additional, Spina, Francesco, additional, Latargia, Maria Luisa, additional, Spedini, Pierangelo, additional, Artale, Salvatore, additional, Anghilieri, Michela, additional, Carraro, Maria Cristina, additional, Bucelli, Cristina, additional, De Canal, Gabriella, additional, Morra, Enrica, additional, and Cairoli, Roberto, additional

Published
2019
Full Text
View/download PDF

29. Nilotinib interferes with cell cycle, ABC transporters and JAK-STAT signaling pathway in CD34+/lin- cells of patients with chronic phase chronic myeloid leukemia after 12 months of treatment

Author

Trojani, Alessandra, primary, Pungolino, Ester, additional, Dal Molin, Alessandra, additional, Lodola, Milena, additional, Rossi, Giuseppe, additional, D’Adda, Mariella, additional, Perego, Alessandra, additional, Elena, Chiara, additional, Turrini, Mauro, additional, Borin, Lorenza, additional, Bucelli, Cristina, additional, Malato, Simona, additional, Carraro, Maria Cristina, additional, Spina, Francesco, additional, Latargia, Maria Luisa, additional, Artale, Salvatore, additional, Spedini, Pierangelo, additional, Anghilieri, Michela, additional, Di Camillo, Barbara, additional, Baruzzo, Giacomo, additional, De Canal, Gabriella, additional, Iurlo, Alessandra, additional, Morra, Enrica, additional, and Cairoli, Roberto, additional

Published
2019
Full Text
View/download PDF

30. FZD6 triggers Wnt–signalling driven by WNT10BIVS1 expression and highlights new targets in T‐cell acute lymphoblastic leukemia.

Author

Cassaro, Adriana, Grillo, Giovanni, Notaro, Marco, Gliozzo, Jessica, Esposito, Ilaria, Reda, Gianluigi, Trojani, Alessandra, Valentini, Giorgio, Di Camillo, Barbara, Cairoli, Roberto, and Beghini, Alessandro

Subjects
LYMPHOBLASTIC leukemia, SMALL interfering RNA, ACUTE leukemia, HEMATOPOIETIC stem cells, ACUTE myeloid leukemia, GENE silencing
Abstract

Wnt/Fzd signaling has been implicated in hematopoietic stem cell maintenance and in acute leukemia establishment. In our previous work, we described a recurrent rearrangement involving the WNT10B locus (WNT10BR), characterized by the expression of WNT10BIVS1 transcript variant, in acute myeloid leukemia. To determine the occurrence of WNT10BR in T‐cell acute lymphoblastic leukemia (T‐ALL), we retrospectively analyzed an Italian cohort of patients (n = 20) and detected a high incidence (13/20) of WNT10BIVS1 expression. To address genes involved in WNT10B molecular response, we have designed a Wnt‐targeted RNA sequencing panel. Identifying Wnt agonists and antagonists, it results that the expression of FZD6, LRP5, and PROM1 genes stands out in WNT10BIVS1 positive patients compared to negative ones. Using MOLT4 and MUTZ‐2 as leukemic cell models, which are characterized by the expression of WNT10BIVS1, we have observed that WNT10B drives major Wnt activation to the FZD6 receptor complex through receipt of ligand. Additionally, short hairpin RNAs (shRNAs)‐mediated gene silencing and small molecule‐mediated inhibition of WNTs secretion have been observed to interfere with the WNT10B/FZD6 interaction. We have therefore identified that WNT10BIVS1 knockdown, or pharmacological interference by the LGK974 porcupine (PORCN) inhibitor, reduces WNT10B/FZD6 protein complex formation and significantly impairs intracellular effectors and leukemic expansion. These results describe the molecular circuit induced by WNT10B and suggest WNT10B/FZD6 as a new target in the T‐ALL treatment strategy. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

31. Nilotinib Deregulates Cell Cycle Checkpoints, ABC Transporters Genes and JAK-STAT Signaling Pathway of CD34+/Lin- Cells in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients after 12 Months of Treatment

Author

Lodola Milena, Morra Enrica, Giacomo Baruzzo, Anghilieri Michela, Carraro Maria Cristina, Lorenza Borin, Elena Chiara, Pungolino Ester, Rossi Giuseppe, Artale Salvatore, Gabriella De Canal, Turrini Mauro, Spina Francesco, Bucelli Cristina, Trojani Alessandra, D'adda Mariella, Malato Simona, Perego Alessandra, Iurlo Alessandra, Spedini Pierangelo, Alessandra Dal Molin, Cairoli Roberto, Maria Luisa Latargia, Trojani, A, Pungolino, E, Rossi, G, D'Adda, M, Lodola, M, Dal Molin, A, Baruzzo, G, Perego, A, Turrini, M, Elena, C, Borin, L, Iurlo, A, Malato, S, Spina, F, Latargia, M, Spedini, P, Artale, S, Anghilieri, M, Cristina, C, Bucelli, C, De Canal, G, Morra, E, and Cairoli, R

Subjects
Oncology, education.field_of_study, medicine.medical_specialty, business.industry, Immunology, Population, CD34, Myeloid leukemia, Cell Biology, Hematology, Cell cycle, Biochemistry, Gene expression profiling, medicine.anatomical_structure, Nilotinib, Internal medicine, medicine, Bone marrow, Stem cell, education, business, medicine.drug
Abstract

Introduction Chronic myeloid leukemia (CML) is a stem cell disease characterized by the constitutive activity of the oncoprotein BCR-ABL that activates multiple signal transduction pathways. Tyrosine-kinase inhibitor (TKI) nilotinib successfully inhibits the activation and the proliferative function of BCR-ABL in patients with CP-CML. Despite the success of nilotinib, some patients become refractory suggesting the presence of a population of Philadelphia positive (Ph+) quiescent stem cells escaping the drug activity. Thus, the molecular mechanisms underlying CML remain poorly understood. In this study, we enrolled 87 CP-CML patients (Pungolino et. al. Am J Hematol. 2018). Samples were collected on the behalf of the Rete Ematologica Lombarda (REL) the PhilosoPhi34 study (EudraCT: 2012-005062-34), which included 15 centers from Italy. We undertook gene expression profiling (GEP) of selected bone marrow (BM) CD34+/lin- cells of 80 patients at diagnosis vs. the same patients after 12 months of nilotinib to investigate gene expression changes induced by the treatment. Methods We isolated CD34+/lin- cells from BM samples in 87 patients at diagnosis whereas the same cells were also selected from 80/87 patients after 3, 6 and 12 months of nilotinib (Trojani et. al. Cancer Biomark. 2017). BM mononuclear cells (MNCs) as well as BM CD34+/lin- cells of all 80 CML patients were counted at diagnosis and during the treatment with nilotinib (at 3, 6, and 12 months, respectively). Standard FISH tested isolated BM CD34/lin- cells for the 87 patients at diagnosis, and for 80/87 patients after 3, 6 and 12 months of nilotinib treatment, respectively. Therefore, we performed GEP analyses of selected BM CD34+/lin- cells of 80/87 patients at diagnosis vs. the same patients after 12 months of nilotinib treatment. Then, we executed bioinformatic preprocessing and correction for batch effects on raw microarray data. Finally, we conducted differential expression analysis and significantly perturbed genes were subjected to functional clustering. Results We observed a wide variability of the number of BM MNCs as well as the number of the BM CD34+/lin- cells among the 80 CP-CML patients at diagnosis and after 3, 6 and 12 months of nilotinib for each patient (Table 1). Figure 1 showed that the number of the BM CD34+/lin- cells dramatically decreased between the diagnosis and after 3 as well as 6 months of nilotinib. We noticed that the BM CD34+/lin- cells slightly increased between 6 and 12 months of nilotinib which might be caused by the gradual repopulation of the normal CD34+/lin- cells in the bone marrow as FISH results suggested. FISH analysis detected CD34+/lin- Ph+ cells in 87 CP-CML patients at diagnosis. No positive Ph+ nuclei were detected on CD34+/lin- cells of 79/80 patients after 12 months of treatment (to categorize a sample as negative, at least 200 nuclei were examined). All of these 79 patients achieved at least complete cytogenetic response. 1/80 patient relapsed at 12 months. We conducted GEP analyses on 78 subjects because, due to experimental issues, two patients were not considered for differential expression analyses, as the microarray CEL files of the 12 months' samples were corrupted and missed probe intensities for most of the probes. GEP analyses determined 2,959 significantly differently expressed probes between diagnosis and after 12 months of nilotinib treatment. Functional clustering identified some pathways significantly enriched between diagnosis and 12 months of nilotinib. Among these pathways, we found that ABCC4, ABCC5, and ABCD3 genes associated with ATP-binding cassette (ABC) transporters were up regulated at diagnosis. GEP results highlighted that 26 genes belonging to cell cycle, mitosis, DNA damage and repair were over expressed at diagnosis. Moreover, GEP data demonstrated that JAK-STAT signaling pathway was deregulated: JAK2, IL7, STAM, PIK3CA, PTPN11, RAF1, SOS1 were over expressed whereas IL22RA1 was under expressed at diagnosis vs. 12 months of nilotinib, respectively. Conclusions In summary, we reported that BM CD34+/lin- cells from CP-CML patients after 12 months of nilotinib were characterized by changes of expression of genes involved in cell cycle checkpoints and mitosis, ABC transporters genes that pump drugs outside form the cells, and JAK-STAT signaling pathway genes responsible for the proliferation, differentiation and cell survival in CML. Disclosures Rossi: Teva: Membership on an entity's Board of Directors or advisory committees; Sanofi: Membership on an entity's Board of Directors or advisory committees; Abbvie: Membership on an entity's Board of Directors or advisory committees; Pfizer: Membership on an entity's Board of Directors or advisory committees; Jazz: Membership on an entity's Board of Directors or advisory committees; Novartis: Honoraria; Mundipharma: Honoraria; BMS: Honoraria; Sandoz: Honoraria; Gilead: Membership on an entity's Board of Directors or advisory committees; Amgen: Membership on an entity's Board of Directors or advisory committees; Celgene: Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees; Roche: Membership on an entity's Board of Directors or advisory committees.

Published
2018

33. Jak-2 and Nfkbia Gene Expression Play a Strategic Role in Chronic Myeloid Leukemia (CML) Molecular Response during Early Nilotinib Treatment: The PhilosoPhi34 Data

Author

Pungolino, Ester, primary, D'adda, Mariella, additional, Trojani, Alessandra, additional, Perego, Alessandra, additional, Elena, Chiara, additional, Iurlo, Alessandra, additional, Malato, Simona, additional, Turrini, Mauro, additional, De Canal, Gabriella, additional, Borin, Lorenza, additional, Lodola, Milena, additional, Caramella, Marianna, additional, Artale, Salvatore, additional, Spina, Francesco, additional, Latargia, Maria Luisa, additional, Anghilieri, Michela, additional, Spedini, Pierangelo, additional, Carraro, Mariacristina, additional, Di Camillo, Barbara, additional, Gramegna, Doriana, additional, Pioltelli, Maria Luisa, additional, Rossi, Giuseppe, additional, Morra, Enrica, additional, and Cairoli, Roberto, additional

Published
2018
Full Text
View/download PDF

34. Nilotinib Deregulates Cell Cycle Checkpoints, ABC Transporters Genes and JAK-STAT Signaling Pathway of CD34+/Lin- Cells in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients after 12 Months of Treatment

Author

Trojani, Alessandra, primary, Pungolino, Ester, additional, Rossi, Giuseppe, additional, D'adda, Mariella, additional, Lodola, Milena, additional, Dal Molin, Alessandra, additional, Baruzzo, Giacomo, additional, Perego, Alessandra, additional, Turrini, Mauro, additional, Elena, Chiara, additional, Borin, Lorenza Maria, additional, Iurlo, Alessandra, additional, Malato, Simona, additional, Spina, Francesco, additional, Latargia, Maria Luisa, additional, Spedini, Pierangelo, additional, Artale, Salvatore, additional, Anghilieri, Michela, additional, Maria Cristina, Carraro, additional, Bucelli, Cristina, additional, De Canal, Gabriella, additional, Morra, Enrica, additional, and Cairoli, Roberto, additional

Published
2018
Full Text
View/download PDF

35. Combining Imatinib-Following-Nilotinib Treatment in First Line Therapy for Chronic Phase Chronic Myeloid Leukemia. Update from the PhilosoPhi34 Study at 24 Months of Follow-up

Author

Pioltelli, Maria Luisa, primary, Pungolino, Ester, additional, D'adda, Mariella, additional, Elena, Chiara, additional, Borin, Lorenza Maria, additional, Perego, Alessandra, additional, Iurlo, Alessandra, additional, Trojani, Alessandra, additional, Turrini, Mauro, additional, Caramella, Marianna, additional, Spedini, Pierangelo, additional, Malato, Simona, additional, Spina, Francesco, additional, Artale, Salvatore, additional, Carraro, Mariacristina, additional, Orofino, Nicola, additional, Anghilieri, Michela, additional, Farina, Mirko, additional, Latargia, Maria Luisa, additional, Rossi, Giuseppe, additional, Morra, Enrica, additional, and Cairoli, Roberto, additional

Published
2018
Full Text
View/download PDF

36. Nilotinib induced bone marrow CD34+/lin-Ph+ cells early clearance in newly diagnosed CP-chronic myeloid leukemia

Author

Pungolino, Ester, primary, Rossi, Giuseppe, additional, De Canal, Gabriella, additional, Trojani, Alessandra, additional, D'adda, Mariella, additional, Perego, Alessandra, additional, Orlandi, Ester Maria, additional, Lunghi, Francesca, additional, Turrini, Mauro, additional, Borin, Lorenza, additional, Iurlo, Alessandra, additional, Latargia, Maria Luisa, additional, Carraro, Maria Cristina, additional, Spina, Francesco, additional, Lodola, Milena, additional, Artale, Salvatore, additional, Anghilieri, Michela, additional, Spedini, Pierangelo, additional, Cantoni, Silvia, additional, Di Camillo, Barbara, additional, Morra, Enrica, additional, and Cairoli, Roberto, additional

Published
2018
Full Text
View/download PDF

37. Wide-transcriptome analysis and cellularity of bone marrow CD34+/lin- cells of patients with chronic-phase chronic myeloid leukemia at diagnosis vs. 12 months of first-line nilotinib treatment

Author

Trojani, Alessandra, primary, Pungolino, Ester, additional, Rossi, Giuseppe, additional, D’Adda, Mariella, additional, Lodola, Milena, additional, Camillo, Barbara Di, additional, Perego, Alessandra, additional, Turrini, Mauro, additional, Orlandi, Ester, additional, Borin, Lorenza, additional, Iurlo, Alessandra, additional, Malato, Simona, additional, Spina, Francesco, additional, Latargia, Maria Luisa, additional, Lanza, Francesco, additional, Artale, Salvatore, additional, Anghilieri, Michela, additional, Carraro, Maria Cristina, additional, Canal, Gabriella De, additional, Morra, Enrica, additional, and Cairoli, Roberto, additional

Published
2017
Full Text
View/download PDF

38. Transcriptome Analysis Identified Significant Differences in Gene Expression Variability Between WM and IgM-MGUS BM B Cell Clones

Author

Trojani, Alessandra, primary, Lodola, Milena, additional, Tedeschi, Alessandra, additional, Greco, Antonino, additional, Di Camillo, Barbara, additional, Sanavia, Tiziana, additional, Frustaci, Anna Maria, additional, Mazzucchelli, Maddalena, additional, Villa, Chiara, additional, Boselli, Daniela, additional, Morra, Enrica, additional, and Cairoli, Roberto, additional

Published
2016
Full Text
View/download PDF

39. The REL-Protocol PhilosoPhi34 - an Open Label, Single Arm, Phase II Study of Nilotinib 300 Mg BID in Newly Diagnosed Chronic Phase Chronic Myeloid Leukaemia (CML) Patients - Confirms Early Clearance of Bone Marrow CD34+/Lin-Ph+ Cells

Author

Pungolino, Ester, primary, De Canal, Gabriella, additional, D'adda, Mariella, additional, Perego, Alessandra, additional, Turrini, Mauro, additional, Orlandi, Ester Maria, additional, Trojani, Alessandra, additional, Borin, Lorenza, additional, Iurlo, Alessandra, additional, Latargia, Maria Luisa, additional, Malato, Simona, additional, Carraro, Maria Cristina, additional, Brusorio, Stefania, additional, Elena, Chiara, additional, Spina, Francesco, additional, Lodola, Milena, additional, Artale, Salvatore, additional, Anghilieri, Michela, additional, Bucelli, Cristina, additional, Pioltelli, Maria Luisa, additional, Cantoni, Silvia, additional, Rossi, Giuseppe, additional, Morra, Enrica, additional, and Cairoli, Roberto, additional

Published
2016
Full Text
View/download PDF

40. Clonal architecture ofCXCR4WHIM-like mutations in Waldenström Macroglobulinaemia

Author

Xu, Lian, primary, Hunter, Zachary R., additional, Tsakmaklis, Nicholas, additional, Cao, Yang, additional, Yang, Guang, additional, Chen, Jie, additional, Liu, Xia, additional, Kanan, Sandra, additional, Castillo, Jorge J., additional, Tai, Yu-Tzu, additional, Zehnder, James L., additional, Brown, Jennifer R., additional, Carrasco, Ruben D., additional, Advani, Ranjana, additional, Sabile, Jean M., additional, Argyropoulos, Kimon, additional, Lia Palomba, M., additional, Morra, Enrica, additional, Trojani, Alessandra, additional, Greco, Antonino, additional, Tedeschi, Alessandra, additional, Varettoni, Marzia, additional, Arcaini, Luca, additional, Munshi, Nikhil M., additional, Anderson, Kenneth C., additional, and Treon, Steven P., additional

Published
2015
Full Text
View/download PDF

41. The Clonal Architecture of CXCR4mutations in Waldenstrom's Macroglobulinemia Shows Highly Variable Subclonal Distribution, and Multiple Mutations within Individual Patients Indicative of Targeted Genomic Instability

Author

Xu, Lian, primary, Hunter, Zachary, additional, Tsakmaklis, Nicholas, additional, Cao, Yang, additional, Yang, Guang, additional, Chen, Jie, additional, Liu, Xia, additional, Kanan, Sandra, additional, Castillo, Jorge J, additional, Tai, Yu-Tzu, additional, Zehnder, James L., additional, Brown, Jennifer R., additional, Carrasco, Ruben D., additional, Advani, Ranjana H, additional, Argyropoulos, Kimon V., additional, Palomba, M. Lia, additional, Morra, Enrica, additional, Trojani, Alessandra, additional, Greco, Antonino, additional, Tedeschi, Alessandra, additional, Varettoni, Marzia, additional, Arcaini, Luca, additional, Munshi, Nikhil C., additional, Anderson, Kenneth C, additional, and Treon, Steven P, additional

Published
2015
Full Text
View/download PDF

42. GEP Analyses of Bone Marrow CD34+/Lin- Cells of Chronic Phase CML Patients at Diagnosis Identified Different Sets of Genes Associated to the Molecular Response after 3 and 6 Months of First-Line Nilotinib Treatment

Author

Trojani, Alessandra, primary, Pungolino, Ester, additional, Lodola, Milena, additional, Di Camillo, Barbara, additional, D'Adda, Mariella, additional, Perego, Alessandra, additional, Turrini, Mauro, additional, Elena, Chiara, additional, Iurlo, Alessandra, additional, Buccelli, Cristina, additional, Malato, Simona, additional, Spina, Francesco, additional, Latargia, Maria Luisa, additional, Lanza, Francesco, additional, Pauli, Sergio, additional, Anghilieri, Michela, additional, Carraro, Maria Cristina, additional, Morra, Enrica, additional, and Cairoli, Roberto, additional

Published
2015
Full Text
View/download PDF

43. REL-Protocol PhilosoPhi34: An Open Label, Single Arm, Phase II Study of Nilotinib 300 Mg BID in Newly Diagnosed Chronic Phase Chronic Myeloid Leukaemia Patients, to Study the Disappearance of CD34+/Lin-Ph+ Cells from Bone Marrow during Treatment. Preliminary Data

Author

Pungolino, Ester, primary, Rossi, Giuseppe, additional, Mura, Maria Angela, additional, Perego, Alessandra, additional, Orlandi, Ester Maria, additional, Turrini, Mauro, additional, Borin, Lorenza, additional, Capucci, Maria Adele, additional, Iurlo, Alessandra, additional, Trojani, Alessandra, additional, D'Adda, Mariella, additional, Spina, Francesco, additional, De Canal, Gabriella, additional, Pioltelli, Maria Luisa, additional, Latargia, Maria Luisa, additional, Pauli, Sergio, additional, Elena, Chiara, additional, Brusorio, Stefania, additional, Lanza, Francesco, additional, Malato, Simona, additional, Anghilieri, Michela, additional, Carraro, Maria C, additional, Morra, Enrica, additional, and Cairoli, Roberto, additional

Published
2015
Full Text
View/download PDF

44. Gene Expression Profiling and Cellularity of Bone Marrow CD34+/Lin- Cells of Patients with Chronic-Phase Chronic Myeloid Leukemia at Diagnosis Vs. 12 Months of First-Line Nilotinib Treatment

Author

Trojani, Alessandra, Pungolino, Ester, Rossi, Giuseppe, D'Adda, Mariella, Lodola, Milena, Di Camillo, Barbara, Perego, Alessandra, Turrini, Mauro, Orlandi, Ester Maria, Borin, Lorenza Maria, Iurlo, Alessandra, Malato, Simona, Spina, Francesco, Latargia, Maria Luisa, Lanza, Francesco, Artale, Salvatore, Anghilieri, Michela, Maria Cristina, Carraro, Bucelli, Cristina, De Canal, Gabriella, Morra, Enrica, and Cairoli, Roberto

Published
2017
Full Text
View/download PDF

45. Preliminary Experience of Imatinib after Nilotinib in the First Line Treatment of Chronic Myeloid Leukemia

Author

Pungolino, Ester, D'adda, Mariella, Perego, Alessandra, Orlandi, Ester Maria, Turrini, Mauro, Borin, Lorenza Maria, Iurlo, Alessandra, Artale, Salvatore, Latargia, Maria Luisa, Anghilieri, Michela, Malato, Simona, Trojani, Alessandra, Spina, Francesco, Maria Cristina, Carraro, Pioltelli, Maria Luisa, Elena, Chiara, Bucelli, Cristina, Spedini, Pierangelo, Rossi, Giuseppe, Morra, Enrica, and Cairoli, Roberto

Published
2017
Full Text
View/download PDF

47. Microarray of Bone Marrow CD34+/Lin- Cells from Patients with Chronic Myeloid Leukemia (CML)

Author

Trojani, Alessandra, primary, Lodola, Milena, additional, Di Camillo, Barbara, additional, Rossi, Giuseppe, additional, Capucci, Adele, additional, Perego, Alessandra, additional, Pogliani, Enrico Maria, additional, Orlandi, Ester, additional, Iurlo, Alessandra, additional, Malato, Simona, additional, Corradini, Paolo, additional, Cairoli, Roberto, additional, Bregni, Marco, additional, Pauli, Sergio, additional, Morra, Enrica, additional, and Pungolino, Ester, additional

Published
2014
Full Text
View/download PDF

48. Gene Expression Profiling of CD34+/Lin- Cells of Patients with Chronic Myeloid Leukemia at Diagnosis and after 12 Months of Nilotinib

Author

Trojani, Alessandra, primary, Lodola, Milena, additional, Di Camillo, Barbara, additional, Rossi, Giuseppe, additional, Capucci, Adele, additional, Perego, Alessandra, additional, Pogliani, Enrico Maria, additional, Orlandi, Ester, additional, Iurlo, Alessandra, additional, Malato, Simona, additional, Corradini, Paolo, additional, Cairoli, Roberto, additional, Bregni, Marco, additional, Artale, Salvatore, additional, Morra, Enrica, additional, and Pungolino, Ester, additional

Published
2014
Full Text
View/download PDF

50. Characterization Of Genes and Pathways From The Comparison Between Bone Marrow B Cells As Well As Plasma Cells Of Waldenström Macroglobulinemia (WM) Vs. IgM Monoclonal Gammopathy Of Undetermined Significance (IgM-MGUS) Vs. Healthy Subjects Using Gene Profiling

Author

Trojani, Alessandra, primary, Lodola, Milena, additional, Greco, Antonino, additional, Tedeschi, Alessandra, additional, Di Camillo, Barbara, additional, Ricci, Francesca, additional, Frustaci, Anna Maria, additional, Turrini, Mauro, additional, and Morra, Enrica, additional

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results